Published in Antivir Ther on January 01, 2007
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother (2009) 0.99
Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther (2009) 0.90
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, Mali. AIDS Res Hum Retroviruses (2012) 0.79
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes. Viruses (2014) 0.79
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Hand hygiene among physicians: performance, beliefs, and perceptions. Ann Intern Med (2004) 4.63
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol (2005) 2.57
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Kaposi's sarcoma in HIV-negative men having sex with men. AIDS (2008) 2.28
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS (2008) 2.27
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS (2008) 2.19
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 2.14
Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med (2004) 2.08
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis (2006) 2.02
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis (2012) 1.80
Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog (2010) 1.73
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS (2010) 1.65
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 1.64
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis (2013) 1.60
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother (2009) 1.59
Diagnosing Treponema pallidum in secondary syphilis by PCR and immunohistochemistry. J Invest Dermatol (2007) 1.58
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study. PLoS One (2012) 1.56
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother (2009) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One (2007) 1.49
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (2011) 1.47
Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection. Am J Respir Crit Care Med (2014) 1.45
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS (2005) 1.45
The marriage of science and optimized HIV care in resource-limited settings. AIDS (2008) 1.44
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.44
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med (2005) 1.43
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS (2004) 1.42
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS (2005) 1.40
Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis (2012) 1.39
Non-sexually related acute genital ulcers in 13 pubertal girls: a clinical and microbiological study. Arch Dermatol (2009) 1.36
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS (2012) 1.36
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS (2002) 1.35
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment. AIDS (2007) 1.34
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol (2009) 1.33
Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis (2012) 1.32
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother (2003) 1.31